期刊文献+

沙利度胺联合FOLFOX4方案治疗晚期结直肠癌的临床观察 被引量:2

Clinical study of FOLFOX4 plus thalidomide in the treatment of advanced intestinal cancers
在线阅读 免费下载
分享 导出
摘要 目的 观察沙利度胺联合FOLFOX4方案对晚期结直肠癌的疗效及不良反应.方法 38例晚期结直肠癌患者口服沙利度胺200 mg/d,服用1~10 d;同时奥沙利铂85 mg/m2静脉滴注2 h第1天,甲酰四氢叶酸(CF)200 mg/m2静脉滴注第1、2天,5-氟尿嘧啶(5-FU)400 mg/m2静脉推注第1、2天,5-FU600 mg/m2静脉滴注22 h第1~2天,每2周重复,4周期后评定疗效,按照WHO实体瘤近期客观疗效评定标准进行评价.结果 38例中CR 4例(10.52%),PR 17例(44.74%),SD 11例(28.95%),PD 6例(15.79%),总有效率(CR+PR)55.26%.主要不良反应为神经系统毒性、恶心呕吐、白细胞降低.结论 沙利度胺联合FOLFOX4方案治疗晚期结直肠癌疗效肯定,安全性较好. Objective To observe the therapeutic effects and adverse effect,which consists of thalidomide combined with biweekly regimen of leucovorin,5-fluorouracil and oxaliplatin(FOLFOX4)in treatment of advanced intestinal cancers.Methods 38 patients with advanced intestinal cancers received thalidomide(200 mg/d,d1-10),chemotherapy of regimen L-OHP 85 mg/m2 2 hours iv on day1,CF200 mg/m2 2 hours iv on day 1 to 2,followed by 5-FU400 mg/m2 iv and 600 mg/m2 22 hours on day 1 to 2,two weeks as one circle.Efficacy was evaluated after 4 circles.Results Four patients achieved complete response(CR),17 patients partial response(PR),11 patients stable disease(SD),6 patients progression disease(PD).Overal response rate was 55.26%.The major toxicity include neurosensory,nausea,vomiting,leucopenia.Conclusion This study shows that the regimen of thalidomide combined FOLFOX4 is effective and tolerable in advanced intestinal cancers.
作者 董亮亮 张良明 DONG Liang-liang  ZHANG Liang-ming 
出处 《中国现代药物应用》 2007年第9期 28-29,共2页
关键词 沙利度胺 奥沙利铂 亚叶酸钙 化学治疗 Thalidomide Oxaliplatin 5-fluorouracil Leucovorin Chemotherapy
  • 相关文献

参考文献9

  • 1孙燕主编..内科肿瘤学[M],2001:1016.
  • 2[2]Raymond E,Chaney SG,Taamma A,et al.Oxaliplatin:a review of preclinical and clinical studies.Ann Oncol,1998,9 (11):1053-1071. 被引量:1
  • 3[3]Saris CP,PGM van de Vaart,Ritbrock RC,et al.In vitro formation of DNA adducts by cisplatin,lobaplatin and oxaliplatin in calf thymus DNA in solution and incultured human cells.Carcinogenesis,1996,17(16):2763-2769. 被引量:1
  • 4[4]deGramont,Vignoud J,Torunigand C,et al.Oxaliplatin with leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.Eur J Cancer,1997,33:214-219. 被引量:1
  • 5[5]Davies F E,RAJE N,Hideshim A T,et al.Thalidomide immunomodulatory derivatives augment nautual killer cell cytotoxicity in multiple myeloma.Blood,2001,98(1):210-216. 被引量:1
  • 6[6]Kabbinavar F,Hurwitz H,Fehrenbacher L,et al.Phase Ⅱ radomized trial comparing Bevacizumab plus fluorouracil(FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol,2003,21:60-65. 被引量:1
  • 7[7]The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer:interim data from the ECOG 3200 trial.Clin Colorectal Cancer,2005,4(5):300-1.No abstract available. 被引量:1
  • 8[8]Jin SH,Kim TI,Han DS,et al.Thalidomide suppresses the interleukin 1 beta-induced NFkappaB signaling pathway in colon cancer cells.Ann N Y Acad Sci,2002,973:414-418. 被引量:1
  • 9[9]Dal Lago L,Richter MF,Cancela AI,et al.Phase Ⅱ trial and pharmacokinetic study fo thalidomide in patients with metastatic coloretal cancer.Invest New Drugs,2003,21 (3):359-366. 被引量:1

同被引文献30

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈